Omeros (OMER) Return on Invested Capital (2026)
Omeros recorded quarterly Return on Invested Capital of 0.0% in Q1 2026.
Omeros' Return on Invested Capital history runs 1 years deep, the most recent figure standing at 0.0% for Q1 2026.
- In Q1 2026, Return on Invested Capital changed N/A year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed N/A YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
- Return on Invested Capital came in at 0.0% for Q1 2026 at Omeros.
- In the past five years, Return on Invested Capital ranged from a high of 0.0% in Q1 2026 to a low of 0.0% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |